IL13RA2 and neoplasm: CAR T cells against tumor-specific antigens, including epidermal growth factor receptor variant III (EGFRvIII), human epidermal growth factor receptor 2 (HER2), and interleukin 13 receptor alpha 2 subunit (IL13Rα2) of glioblastoma (GBM), were under clinical studies to collect data about their safety and feasibility in recent years.